Alnylam Presents Detailed Results From Positive HELIOS-B Phase 3 Study Of Vutrisiran: Achieved 28% Reduction In Primary Composite Of All-cause Mortality And Recurrent Cardiovascular Events, And 31% And 36% Reductions In All-cause Mortality
Portfolio Pulse from Nabaparna Bhattacharya
Alnylam Pharmaceuticals announced positive results from its HELIOS-B Phase 3 study of Vutrisiran, showing significant reductions in all-cause mortality and cardiovascular events.

August 30, 2024 | 10:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals' HELIOS-B Phase 3 study of Vutrisiran showed a 28% reduction in all-cause mortality and cardiovascular events, and further reductions in mortality alone, indicating strong efficacy.
The positive Phase 3 results for Vutrisiran are likely to boost investor confidence in Alnylam Pharmaceuticals, as the drug shows significant efficacy in reducing mortality and cardiovascular events. This could lead to increased stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100